Inhibition of PLD1, when combined with vorinostat, significantly reduces GBM invasiveness, angiogenesis, self-renewal, and intracranial tumor formation, effectively overcoming resistance to conventional therapies. This evidence concerns the gene PLD1 and glioblastoma.